Table 4.
The Correlation Between CTV/(GTV+GTVnd) and Dose Reductions of OARs in SIB-VAMT Plans
| Variables | Decreased Proportions (%) | P-value | |
|---|---|---|---|
| Group A [CTV/(GTV+GTVnd)<8.6] | Group B [CTV/(GTV+GTVnd) ≥ 8.6] | ||
| Lung | |||
| MLD | 6.3(4.3–14.5) | 7.5(4–13.1) | 0.211 |
| V5 | 3.2(−0.7–7.6) | 4.3(−2.2–10) | 0.242 |
| V10 | 0(−4.3–9.8) | 1.4(−4.1–4.9) | 0.327 |
| V20 | −0.4(−7.1–21.3) | −0.2(−7.7–5.6) | 0.841 |
| V30 | 8.8(0.2–23.8) | 8.8(0.5–24.6) | 0.82 |
| V40 | 17.8(1.6–29.8) | 21.9(10.4–31) | 0.157 |
| V50 | 28.8(17.9–38) | 33.6(28–45.5) | 0.001* |
| Esophagus | |||
| Dmax | 8.2(1.6–19.9) | 7.2(1.8–17.5) | 0.583 |
| MLD | 8.2(0.8–15.4) | 11.5(3.9–18.5) | 0.072 |
| V40 | 2.5(−4.0–62) | 1.8(0–17.3) | 0.82 |
| V50 | 12.2(−2.9–94.4) | 7.9(0.5–51.4) | 0.265 |
| Heart | |||
| Dmax | 6.8(2.3–19) | 9.9(2.2–20) | 0.478 |
| MLD | 12(−1.6–22.1) | 11.3(3.6–18.3) | 0.862 |
| V5 | 2.3(−8.9–7.6) | 1.9(−2.7–14) | 0.779 |
| V30 | 25.4(0–53.7) | 26.1(6.1–41.3) | 0.588 |
| V40 | 37.8(−0.2–67.2) | 39.3(22.1–64.8) | 0.336 |
| Spinal cord | |||
| Dmax | 15.9(0–19.1) | 15.6(11.9–21.3) | 0.659 |
| Spinal cord PRV | |||
| Dmax | 14.4(5.7–24.7) | 14.8(7.9–21.4) | 0.883 |
Note: *P<0.05 was considered significant.